Longevity & AgingSingle Gene Therapy Shot Cuts Alzheimer's Tau Protein by 64% in Primates
A single intravenous dose of an experimental gene therapy called VY1706 reduced tau — a protein central to Alzheimer's disease — by up to 64% in key brain regions of non-human primates. Developed by Voyager Therapeutics, the therapy works by silencing the gene that produces tau, cutting its messenger RNA by up to 75%. Crucially, the treatment showed no harmful side effects over a 13-week observation period, even at the highest doses tested. These results come from a formal toxicology study required before human trials. Voyager has filed with the FDA and aims to begin first-in-human dosing in the second half of 2026. If successful in humans, this one-shot approach could represent a major shift in how Alzheimer's is treated or even prevented.
